Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Harold E. Bays, Peter P. Toth, Penny M. Kris-Etherton, Nicola Abate, Louis J. Aronne, W. Virgil Brown, J. Michael Gonzalez-Campoy, Steven R. Jones, Rekha Kumar, Ralph La Forge, Varman T. Samuel

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.

Original languageEnglish (US)
Pages (from-to)304-383
Number of pages80
JournalJournal of Clinical Lipidology
Volume7
Issue number4
DOIs
StatePublished - Jul 1 2013

Fingerprint

Adiposity
Dyslipidemias
Adipose Tissue
Obesity
Lipids
Adipocytes
Fats
Bariatric Surgery
Plant Oils
Hypertrophy
Lipoproteins
Coronary Disease
Triglycerides
Cardiovascular Diseases
Cholesterol
Exercise
Weights and Measures
Therapeutics
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Bays, Harold E. ; Toth, Peter P. ; Kris-Etherton, Penny M. ; Abate, Nicola ; Aronne, Louis J. ; Brown, W. Virgil ; Gonzalez-Campoy, J. Michael ; Jones, Steven R. ; Kumar, Rekha ; La Forge, Ralph ; Samuel, Varman T. / Obesity, adiposity, and dyslipidemia : A consensus statement from the National Lipid Association. In: Journal of Clinical Lipidology. 2013 ; Vol. 7, No. 4. pp. 304-383.
@article{d405346baaa344ac8ce0ef82f1656ca7,
title = "Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association",
abstract = "The term {"}fat{"} may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). {"}Lipid{"} is derived from {"}lipos,{"} which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from {"}adipo,{"} referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.",
author = "Bays, {Harold E.} and Toth, {Peter P.} and Kris-Etherton, {Penny M.} and Nicola Abate and Aronne, {Louis J.} and Brown, {W. Virgil} and Gonzalez-Campoy, {J. Michael} and Jones, {Steven R.} and Rekha Kumar and {La Forge}, Ralph and Samuel, {Varman T.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.jacl.2013.04.001",
language = "English (US)",
volume = "7",
pages = "304--383",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "4",

}

Bays, HE, Toth, PP, Kris-Etherton, PM, Abate, N, Aronne, LJ, Brown, WV, Gonzalez-Campoy, JM, Jones, SR, Kumar, R, La Forge, R & Samuel, VT 2013, 'Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association', Journal of Clinical Lipidology, vol. 7, no. 4, pp. 304-383. https://doi.org/10.1016/j.jacl.2013.04.001

Obesity, adiposity, and dyslipidemia : A consensus statement from the National Lipid Association. / Bays, Harold E.; Toth, Peter P.; Kris-Etherton, Penny M.; Abate, Nicola; Aronne, Louis J.; Brown, W. Virgil; Gonzalez-Campoy, J. Michael; Jones, Steven R.; Kumar, Rekha; La Forge, Ralph; Samuel, Varman T.

In: Journal of Clinical Lipidology, Vol. 7, No. 4, 01.07.2013, p. 304-383.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Obesity, adiposity, and dyslipidemia

T2 - A consensus statement from the National Lipid Association

AU - Bays, Harold E.

AU - Toth, Peter P.

AU - Kris-Etherton, Penny M.

AU - Abate, Nicola

AU - Aronne, Louis J.

AU - Brown, W. Virgil

AU - Gonzalez-Campoy, J. Michael

AU - Jones, Steven R.

AU - Kumar, Rekha

AU - La Forge, Ralph

AU - Samuel, Varman T.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.

AB - The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.

UR - http://www.scopus.com/inward/record.url?scp=84880917866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880917866&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2013.04.001

DO - 10.1016/j.jacl.2013.04.001

M3 - Article

C2 - 23890517

AN - SCOPUS:84880917866

VL - 7

SP - 304

EP - 383

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 4

ER -